3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Metabolic Solutions Development Company
ClinicalTrials.gov Identifier:
NCT01374438
First received: June 14, 2011
Last updated: October 30, 2013
Last verified: October 2013
  Purpose

This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this population will also be studied. These results will be used to design larger studies of MSDC-0160 in persons with mild Alzheimer's disease.


Condition Intervention Phase
Alzheimer's Disease
Drug: MSDC-0160
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Metabolic Solutions Development Company:

Primary Outcome Measures:
  • Change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis [ Time Frame: Days 1(baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate of the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The a priori regions of interest (ROI) will include five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex.


Secondary Outcome Measures:
  • FDG-PET voxel-based analysis [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate of the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose utilization, using FDG-PET voxel-based analysis

  • Cognitive function tests [ Time Frame: Days 1 (baseline), 91, and 121 ] [ Designated as safety issue: No ]
    Estimate of the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests.

  • Cognitive function as determined by the ADAS-Cog subscale [ Time Frame: Days 1 (baseline), 91 and 121 ] [ Designated as safety issue: No ]
    Estimate of the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale.

  • Cognitive function as estimate with the executive function scale [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale.

  • Correlation between baseline peripheral inflammatory biomarkers, genotype, and brain glucose utilization [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin, TNFα, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the apolipoprotein ε4 allele explain the heterogeneity in baseline level of brain glucose utilization and, in MSDC-0160 users, 3-month brain glucose utilization.

  • Relationship between peripheral inflammatory biomarkers and brain glucose utilization. [ Time Frame: Days 1 (baseline) and 91 ] [ Designated as safety issue: No ]
    Explore whether changes in peripheral inflammatory biomarkers correlate with 3 month changes in brain glucose utilization in MSDC-0160 users.

  • Safety and tolerability of MSDC-0160 in this population [ Time Frame: Day 1 (baseline) through Day 121 (follow-up) ] [ Designated as safety issue: No ]
    Investigate the safety and tolerability of MSDC-0160 using reports of early study termination and adverse events.


Enrollment: 29
Study Start Date: July 2011
Study Completion Date: May 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MSDC-0160 capsules
MSDC tablets contained in #00 capsules
Drug: MSDC-0160
MSDC-0160 150 mg capsules given once daily for 90 days
Other Name: Mitoglitazone
Placebo Comparator: Placebo capsules
Placebo tablets contained in #00 capsules
Drug: Placebo
Placebo capsules given once daily for 90 days

Detailed Description:

The specific objective is to examine the feasibility of conducting future large scale studies on the efficacy of MSDC-0160 in persons with mild Alzheimer's disease. Efficacy and safety will be assessed as follows:

  1. Estimate the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The a priori regions of interest (ROI) will include five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex.
  2. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose utilization, using FDG-PET voxel-based analysis.
  3. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests.
  4. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale.
  5. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale.
  6. Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin, TNFα, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the apolipoprotein ε4 allele explain the heterogeneity in baseline level of brain glucose utilization and, in MSDC-0160 users, 3-month brain glucose utilization.
  7. Explore whether changes in peripheral inflammatory biomarkers correlate with changes in 3-month brain glucose utilization in MSDC-0160 users.
  8. Investigate the safety of MSDC-0160 versus placebo using reports of early study termination and adverse events.
  Eligibility

Ages Eligible for Study:   55 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or females 55-85 years of age.
  2. Females should be either postmenopausal or surgically sterilized. Males with female partners of child-bearing potential must use contraception if engaging in sexual intercourse.
  3. Diagnosis of probable Alzheimer's disease based on NIA-AA criteria with MMSE scores of 20 or greater.
  4. Willing and able to take part in up to six study visits over a 5-month period, with the support of a caregiver as needed.
  5. Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study, with the support of a caregiver as needed.

Exclusion Criteria:

  1. Diagnosis of diabetes, including use of anti-diabetic medications, or fasting plasma glucose >125 mg/dl or Hemoglobin A1c>6.4%.
  2. Unable to participate in FDG-PET scanning, including:

    • Inability to cooperate/claustrophobia (no sedation offered for this protocol).
    • Inability to lie still on the scanner bed for 40 minutes.
    • Total radiation dose exposure to the subject in any given year exceeds the limits of annual and total dose commitment of 50 mSv (5 REMs). The two FDG-PET scans will result in an approximate exposure of 10 mSv (1 REM).
  3. Diagnosis of significant neurological/psychiatric disease other than AD, including, but not limited to, any of the following: vascular dementia according to NINDS-AIREN criteria, space occupying cerebral lesion, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, and seizures.
  4. History of heart failure (including CHF).
  5. Previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to screening.
  6. Inability to undergo a clinical (1.5T) MRI of the brain without contrast and lack of a usable (less the 12 months prior to screening) MRI on record. Contraindications to undergoing an MRI of the brain include, but are not limited to, pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; and, other magnetic, electronic or mechanical implants or clinical findings that in the judgment of the investigator would pose a potential hazard in combination with MRI.
  7. ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine >1.5 mg/dL in men or > 1.4 mg/dL in women.
  8. Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the subject unlikely to complete the study.
  9. Malignancy (other than non-melanoma skin cancer) within the last 5 years.
  10. Known history of HIV, hepatitis B, or hepatitis C.
  11. Blood pressure greater than 160/100 mmHg. Subjects with elevated BP will be allowed at the discretion of the principal investigator. Individuals with hypertension must have been stabilized to the current treatment regimen for at least 6 weeks prior to screening and not need adjustments to their treatment regimen during the entire study period.
  12. Change in other medications to treat Alzheimer's disease within 3 months prior to screening. Change in medication to treat other conditions within 6 weeks prior to screening or during the study period.
  13. Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds, or any of their stated ingredients.
  14. History of alcohol or drug abuse within 6 months of screening.
  15. Have participated in an investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
  16. Single 12-lead ECG demonstrating a QTcB >450 msec or other clinically significant finding at screening. A single repeat ECG may be done at the investigator's discretion.
  17. Any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following: history of major gastrointestinal tract surgery, currently active inflammatory bowel syndrome.
  18. Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01374438

Locations
United States, Illinois
Rush Memorial University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Metabolic Solutions Development Company
Investigators
Study Director: Jerry R Colca, PhD MSDC
Principal Investigator: Raj C. Shah, MD Rush Memorial University Medical Center
  More Information

No publications provided

Responsible Party: Metabolic Solutions Development Company
ClinicalTrials.gov Identifier: NCT01374438     History of Changes
Other Study ID Numbers: MSDC-0160-C006
Study First Received: June 14, 2011
Last Updated: October 30, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Metabolic Solutions Development Company:
Alzheimer's disease
cognitive function
brain glucose utilization
FDG-PET

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 21, 2014